

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

*Antimicrobial Drugs Advisory Committee (AMDAC) Meeting*  
April 17, 2023

**DRAFT QUESTIONS**

---

1. **VOTE:** Is the overall benefit-risk assessment favorable for the use of sulbactam-durlobactam for the treatment of patients with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of *Acinetobacter baumannii-calcoaceticus* complex (ABC) organisms?
  - a. If yes, please provide your rationale.
  - b. If no, please provide your rationale and describe what additional studies/trials are needed.

DRAFT